Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis. / Johansen, Thomas Lund; Kjær, Andreas.

In: BMC Nephrology, Vol. 2, 1, 17.05.2001, p. 1-5.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Johansen, TL & Kjær, A 2001, 'Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis', BMC Nephrology, vol. 2, 1, pp. 1-5. https://doi.org/10.1186/1471-2369-2-1

APA

Johansen, T. L., & Kjær, A. (2001). Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis. BMC Nephrology, 2, 1-5. [1]. https://doi.org/10.1186/1471-2369-2-1

Vancouver

Johansen TL, Kjær A. Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis. BMC Nephrology. 2001 May 17;2:1-5. 1. https://doi.org/10.1186/1471-2369-2-1

Author

Johansen, Thomas Lund ; Kjær, Andreas. / Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis. In: BMC Nephrology. 2001 ; Vol. 2. pp. 1-5.

Bibtex

@article{11d8050890ba402da6b739fdf6cd40f0,
title = "Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis",
abstract = "Background: It is well established that ACE-inhibitors should be avoided in patients with renal artery stenosis. In recent years it has also been recommended that caution should be demonstrated when angiotensin II blockers are used in the same type of patients but the evidence is based only on few cases. Results: We describe a case where use of the angiotensin II antagonist candesartan (Atacand) induced renal failure in a patient with bilateral renal artery stenosis. The course of the case is enlighted by results from sequential renography, selective renal vein catheterisation for measurement of renin, and angiographic findings. Conclusions: In patients with renal artery stenosis the angiotensin II antagonist candesartan should be avoided.",
author = "Johansen, {Thomas Lund} and Andreas Kj{\ae}r",
year = "2001",
month = may,
day = "17",
doi = "10.1186/1471-2369-2-1",
language = "English",
volume = "2",
pages = "1--5",
journal = "BMC Nephrology",
issn = "1471-2369",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis

AU - Johansen, Thomas Lund

AU - Kjær, Andreas

PY - 2001/5/17

Y1 - 2001/5/17

N2 - Background: It is well established that ACE-inhibitors should be avoided in patients with renal artery stenosis. In recent years it has also been recommended that caution should be demonstrated when angiotensin II blockers are used in the same type of patients but the evidence is based only on few cases. Results: We describe a case where use of the angiotensin II antagonist candesartan (Atacand) induced renal failure in a patient with bilateral renal artery stenosis. The course of the case is enlighted by results from sequential renography, selective renal vein catheterisation for measurement of renin, and angiographic findings. Conclusions: In patients with renal artery stenosis the angiotensin II antagonist candesartan should be avoided.

AB - Background: It is well established that ACE-inhibitors should be avoided in patients with renal artery stenosis. In recent years it has also been recommended that caution should be demonstrated when angiotensin II blockers are used in the same type of patients but the evidence is based only on few cases. Results: We describe a case where use of the angiotensin II antagonist candesartan (Atacand) induced renal failure in a patient with bilateral renal artery stenosis. The course of the case is enlighted by results from sequential renography, selective renal vein catheterisation for measurement of renin, and angiographic findings. Conclusions: In patients with renal artery stenosis the angiotensin II antagonist candesartan should be avoided.

UR - http://www.scopus.com/inward/record.url?scp=0001782480&partnerID=8YFLogxK

U2 - 10.1186/1471-2369-2-1

DO - 10.1186/1471-2369-2-1

M3 - Journal article

C2 - 11388887

AN - SCOPUS:0001782480

VL - 2

SP - 1

EP - 5

JO - BMC Nephrology

JF - BMC Nephrology

SN - 1471-2369

M1 - 1

ER -

ID: 283515578